✦ LIBER ✦

CORRIGENDUM: Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The dipeptidyl peptidase-4 inhibitor PHX

✍ G. Garcia-Soria; G. Gonzalez-Galvez; G. M. Argoud; M. Gerstman; T. W. Littlejohn 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

Dutogliptin, a selective DPP4 inhibitor,

✍ H. M. R. Pattzi; S. Pitale; M. Alpizar; C. Bennett; A. M. O’Farrell; J. Li; J. M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

Effect of dapagliflozin in patients with

✍ K. Strojek; K. H. Yoon; V. Hruba; M. Elze; A. M. Langkilde; S. Parikh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Long-term treatment with empagliflozin,

✍ L. Thomas; R. Grempler; M. Eckhardt; F. Himmelsbach; A. Sauer; T. Klein; P. Eick 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

Long-term effects of exenatide therapy o

✍ R. E. Ratner; D. Maggs; L. L. Nielsen; A. H. Stonehouse; T. Poon; B. Zhang; T. A 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

The effect of pramlintide acetate on gly

✍ D. Singh-Franco; A. Perez; C. Harrington 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB